8th May 2020 – Number 2

XENOTHERA NEWS

Official news bulletin for XAV-19

EDITORIAL

by Odile DUVAUX, President of XENOTHERA

To be free, or to submit... in these times of confinement, of possible solitude, of deconfinement, we are each of us brought abruptly face to face with this profoundly human dilemma. Living in a regulated environment, accepting simply because it is the law, or because it is right, in the moral sense of the term, right for me, and / or right for the community. We are faced with a hierarchy of values, and it is not always clear which way the ethical path lies. For the XENOTHERA project, the question is less acute, but there is a similarity nonetheless. A balance must be found, between the legitimate and urgent desire to treat patients, an entrepreneurial impulse that seeks to bend reality according to its desire, and compliance with the thoroughly respectable regulations developed by society, which sometimes slow things down. For XENOTHERA at this time, submitting to expert opinion (see our news) is a comfortable safety net because ultimately, in our dealings with cooperative and competent partners, it is in this submission that we find our zone of freedom.

MAIN FOCUS
Update on XAV-19 news

The news this week is the formal response from ANSM regarding the XAV-19 project. ANSM is the French agency that ensures the safety and regulatory compliance of all clinical trials taking place in France. It is the independent party responsible for approving the approach of pharmaceutical companies wishing to test new treatments or vaccines.

For XENOTHERA, the conversation started a month ago, and in mid-April a formal meeting was set up with eleven experts. This week, XENOTHERA received notice of ANSM's commitment to the next steps. This decision clearly confirms their approval of the approach to the clinical trial, of the safety of the XAV-19 product, and of the evidence that XENOTHERA must provide before being authorised to administer the treatment to patients. This decision means that XENOTHERA can confirm the extremely ambitious schedule that the company drew up in mid-March, namely treatment of the first patients in July.

TESTIMONY
Support of XENOTHERA

This week, Marc Bouillet explains why he supports XENOTHERA.

Go to his forum below to learn about the therapeutic approach of XAV-19:

In the press...

Click on the logos to access articles and reports.

Find our latest press releases:

- XENOTHERA launches support campaign to finalise treatment for coronavirus infections, including Covid-19

- LFB signs agreement with biotech XENOTHERA

- The search for Covid-19 treatments: how can the antibodies developed by the French biotech XENOTHERA help?

XENOTHERA :

XENOTHERA, created in 2014, is a Nantes-based biotech company which develops "humanized" polyclonal antibodies. Their technological platform is based on dual expertise in animal genetics and a mastery of immunology. The company has a complete portfolio of products, the first of which, LIS1, an immunosuppressant for transplants, has been in clinical trials since 2019. XENOTHERA is part of the Nantes scientific, medical and academic environment and is supported by the Pays de la Loire region's Atlanpole competitiveness cluster. Since its creation, the company has raised 6 million euros in equity and has received support from the BPI.
For more information go to www.xenothera.com

Follow XENOTHERA on social media :

Contact :
XENOTHERA
1 rue Vauban - 44 000 Nantes
xenothera@izsogood.co